Questions & Discussion

Patients with retroperitoneal dedifferentiated liposarcoma and leiomyosarcoma are at high risk for developing hematogenous metastatic disease. Although many institutions utilize neoadjuvant chemotherapy, the absolute benefit is not clear. As there is currently no completed randomized prospective study addressing neoadjuvant chemotherapy, the debators will vigorously discuss the pros and cons of this approach.